About this trial
. A glycolytic enzyme called enolase is primarily found in neurons. A dimeric isoform of enolase called neuron-specific enolase (NSE) exists. It can be found in neurons, platelets, erythrocytes, and other neuroectodermal cells.It is one of the laboratory biomarkers that could be investigated in cases of encephalopathy, which can be found in both blood and cerebrospinal fluid, might be a helpful biomarker for determining brain injury prognosis and neuronal damage.(4) High S-100beta levels were associated with higher intensive care unit mortality and represented the strongest independent predictor of intensive care unit survival, whereas neuron-specific enolase (NSE) and the Glasgow Coma Scale failed to predict fatal outcome.(5) (NSE) and S100B are important as a diagnostic and a prognostic value in pediatric encephalopathy which is common and is potentially life threatening, previous studies were done worldwide to detect its diagnostic and prognostic value in acute encephalopathy among adult and pediatric age groups.(4) ,so we asses (NSE) and S100B to detect the the out come of acute encephalopathy
Eligibility criteria
This trial does not accept healthy volunteersQualifiers
1. Pediatric population aged 1month to 18 years.
Decreased level of consciousness, personality change, or psychiatric manifestations lasting >24 h (in toddlers and infants, may present as increased irritability or lethargy)
No alternative diagnosis to explain presentation
Seizure (new onset)
Disqualifiers
1. Neonates and adults ( <1 month or >18 years) 2. If they had a diagnosis of delirium or encephalopathy secondary to sepsis, toxins,renal ,hepatic or metabolic causes (hypoglycemia, electrolyte disturbances
Trial population
1\. Pediatric population aged 1month to 18 years. * Decreased level of consciousness, personality change, or psychiatric manifestations lasting \>24 h (in toddlers and infants, may present as increased irritability or lethargy) * No alternative diagnosis to explain presentation * Seizure (new onset) * Fever (≥38.0°C) * Focal neurologic findings (new onset) * CSF WBC ≥5/mm3 * Acute abnormality on brain MRI
Trial design
Cohort
Prospective
Treatments tested in this trial
CSF analysis and culture including S100B,Neuron Specific Enolase(NSE)
Diagnostic testCSF analysis and culture including S100B,Neuron Specific Enolase(NSE)
Treatment groups
Trial outcomes
Primary outcomes
To asses clinical ,radiological laboratory biomarkers ( CSF Neuron-Specific Enolase and S100B )as outcome predictors of encephalitis
To asses clinical ,radiological laboratory biomarkers ( CSF Neuron-Specific Enolase and S100B )as outcome predictors of encephalitis
Sponsors and contacts
Click on the lead sponsor to view all of their trials.
This trial is not recruiting at the moment. You can still explore other options: